Cg200745, A Novel Hdac Inhibitor, Attenuates Kidney Fibrosis In A Murine Model Of Alport Syndrome

Histone deacetylases have been a target of therapy for organ fibrosis. Here, we report the protective effect of CG200745 (CG), a novel histone deacetylase inhibitor, on tubulointerstitial fibrosis in Col4a3(-/-) mice, a murine model of Alport syndrome. Morphological analyses revealed CG treatment markedly alleviated kidney fibrosis in Col4a3(-/-) mice at the age of 7 weeks. CG prevented the activation of transforming growth factor beta (TGF beta) and its downstream SMAD signaling in the kidney of Col4a3(-/-) mice. As critical upstream regulators of TGF beta signaling, immunoblotting of whole kidney lysate of Col4a3(-/-) mice reveled that intra-renal renin-angiotensin system (RAS) was activated with concurrent upregulation of inflammation and apoptosis, which were effectively suppressed by CG treatment. CG suppressed both activation of RAS and up-regulation of TGF beta signals in angiotensin II-stimulated HK-2 cells, a human kidney proximal tubular epithelial cell line. CG inhibited activation of TGF beta-driven signals and fibrosis in NRK-49F cells, a rat kidney fibroblast cell line, under angiotensin II-rich conditions. Collectively, CG was found to be effective both in proximal tubular epithelial cells by inhibiting local RAS and TGF beta signaling activation, as well as in fibroblasts by blocking their transition to myofibroblasts, attenuating renal fibrosis in a murine model of Alport syndrome.